Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Xeno-Free Propagation of Spermatogonial Stem Cells from Infant Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Propagation of Spermatogonial Stem Cell-Like Cells From Infant Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Associations of different molecular forms of antimüllerian hormone and biomarkers of polycystic ovary syndrome and normal women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sertoli Cell Number Correlates with Serum Inhibin B in Infant Cryptorchid Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Carlo Alviggi
  • Alessandro Conforti
  • Sandro C Esteves
  • Claus Yding Andersen
  • Ernesto Bosch
  • Klaus Bühler
  • Anna Pia Ferraretti
  • Giuseppe De Placido
  • Antonio Mollo
  • Robert Fischer
  • Peter Humaidan
Vis graf over relationer

OBJECTIVE: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients.

DESIGN: Systematic review.

SETTING: Centers for reproductive care.

PATIENT(S): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a "poor response" to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria.

INTERVENTION(S): Systematic review.

MAIN OUTCOME MEASURE(S): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes.

RESULT(S): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation.

CONCLUSION(S): Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.

OriginalsprogEngelsk
TidsskriftFertility and Sterility
Vol/bind109
Udgave nummer4
Sider (fra-til)644-664
Antal sider21
ISSN0015-0282
DOI
StatusUdgivet - 1 apr. 2018

ID: 54949738